Drug profile · INN
lemborexant
DAYVIGO
lemborexant (DAYVIGO) is a orexin receptor 1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — lemborexant
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
lemborexant (DAYVIGO) is a orexin receptor 1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Orexin receptor 1 antagonist
Primary target: Orexin/Hypocretin receptor type 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lemborexant?
lemborexant (DAYVIGO) is a orexin receptor 1 antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lemborexant?
DAYVIGO is a marketed brand name for lemborexant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lemborexant?
lemborexant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.